Robert Orr, U.S. Food and Drug Administration. fda.gov. October 25, 2023.
The 2023 FDA presentation repeats 75F40120C00176 as an FDA/OMHHE collaboration studying COVID-19 illness in diverse populations. It provides a later official account of the same funding relationship described in 2022, rather than a new independent study or award. Nolan’s connection comes from the separate MaxFuse acknowledgement; no classified UAP access is reported.
◧ Partial root native PDF text and selected layout review
Robert Orr, U.S. Food and Drug Administration. fda.gov. December 6, 2022.
Robert Orr’s FDA presentation publicly describes a 2017 modification of contract HHSF223201610018C and links 75F40120C00176 to a collaboration studying COVID-19 illness in diverse populations. These identifiers match contracts acknowledged for Nolan in MaxFuse. The slides document agency statements about public research funding; they do not name Nolan or establish secret invitations or UAP access.
◧ Partial root native PDF text and selected layout review
Martin T. Orne, David F. Dinges, Emily Carota Orne. ojp.gov. December 1984.
Orne, Dinges and Orne’s December 1984 NIJ brief separates confidence and detail from accurate memory, describes risks of suggestion and confabulation, and allows a qualified role for investigative leads while opposing court testimony based on hypnosis. Its safeguards document sessions without guaranteeing accurate recollection. This is a historical review, not a new UFO study or current legal/clinical guidance. Public grant support and agency hosting do not establish a secret programme or agency endorsement of every author conclusion.
■ Complete supplied NIJ brief text and all six scan layouts
An FDA contract listing names Stanford University for 75F40120C00176, independently of the MaxFuse acknowledgement. The requirement concerns coronavirus research. Its wording differs from a later FDA presentation using the same identifier; the amendment or naming history remains unresolved. This supports a public institutional funding link, without establishing Nolan as the named principal investigator or a classified programme.
◧ Partial root native PDF text and selected layout review
The 2024 Edition of this oversight provision distinguishes case-specific withholding from supplying information and justification to committee leadership. Its annual-report wording also carries a termination note referring to December 2021. Cross-referenced provisions and later changes have not been collated, so current application remains unverified. This is historical statutory context for programme-access claims, not evidence that a UAP programme existed or anyone obtained access.
■ Complete returned historical section; current application unreviewed
National Institutes of Health. api.reporter.nih.gov.
Official NIH metadata returns two FY2021 application records for 3U19AI100627-09S2, both naming Scripps as recipient and the same amount. Their contact PIs are Garry P. Nolan and Richard J. Ulevitch; Sage appears in neither PI list. Shared identifiers and differing dates do not establish two independent awards or their administrative relationship. The paper’s Sage/Nolan support acknowledgement is preserved as a different fact from registered PI metadata. No classified approach, agency adoption or UAP involvement is established.
■ Official award metadata only; scientific and award bodies unreviewed
The 2024 Edition sets conditions for presidential covert-action findings and congressional reporting. Restricted access retains reasons, periodic review and committee notice/records. Its covert-action definition concerns unacknowledged overseas influence and excludes specified intelligence, military, diplomatic and other activities; secrecy alone does not establish that classification. The text also prohibits specified domestic influence. This is historical legal context, with later changes and current application unverified; it proves no specific UAP programme or achieved access.
■ Complete historical section scope; current application unreviewed
John E. Shaw (typed signer in author-hosted reproduction). lweb.cfa.harvard.edu. March 1, 2022.
This author-hosted reproduction presents a Space Command memorandum to NASA. Its first paragraph attributes 99.999% confidence to the Siraj–Loeb paper; the second reports Mozer’s qualitative confirmation of a sufficiently accurate velocity estimate. It supplies no raw data, numerical uncertainty analysis or researcher classified access. The page concerns the same meteor chain, rather than a new detection or technological-origin finding.
■ Author-hosted public reproduction read; official authentication unresolved
A curated public selection. Source review describes what was read; it does not establish that a claim is true. Our research approach